← 返回

肺肿瘤 MHCII 免疫依赖于成纤维细胞的原位抗原呈递

英文原题:Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts.

查看英文原题

Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts.

PubMed 2022/01/14(内容时间) J Exp Med Q1 · IF 11.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

肿瘤免疫中功能空间的一个关键未知点是CD4 T细胞是否依赖于瘤内MHCII肿瘤抗原识别。在乳腺和胰腺肿瘤中已发现表达MHCII的抗原呈递癌相关成纤维细胞(apCAFs),并被认为具有免疫抑制作用。本分析显示,抗原呈递成纤维细胞在人类肺非小细胞癌中频繁出现,在那里它们似乎积极促进而非抑制MHCII免疫。肺apCAFs直接激活效应CD4 T细胞的TCR,同时产生C1q,后者作用于T细胞C1qbp以使其免于凋亡。成纤维细胞特异性MHCII或C1q缺失损害了CD4 T细胞免疫并加速了肿瘤生长,而在过继转移的CD4 T细胞中诱导C1qbp则扩大了其数量并减少了肿瘤。总体而言,我们已在肺中表征了一个具有肿瘤抑制特性的抗原呈递成纤维细胞亚群,并提出癌症免疫疗法可能强烈依赖于原位MHCII抗原呈递。

展开英文摘要原文

A key unknown of the functional space in tumor immunity is whether CD4 T cells depend on intratumoral MHCII cancer antigen recognition. MHCII-expressing, antigen-presenting cancer-associated fibroblasts (apCAFs) have been found in breast and pancreatic tumors and are considered to be immunosuppressive. This analysis shows that antigen-presenting fibroblasts are frequent in human lung non-small cell carcinomas, where they seem to actively promote rather than suppress MHCII immunity.

Lung apCAFs directly activated the TCRs of effector CD4 T cells and at the same time produced C1q, which acted on T cell C1qbp to rescue them from apoptosis. Fibroblast-specific MHCII or C1q deletion impaired CD4 T cell immunity and accelerated tumor growth, while inducing C1qbp in adoptively transferred CD4 T cells expanded their numbers and reduced tumors.

Collectively, we have characterized in the lungs a subset of antigen-presenting fibroblasts with tumor-suppressive properties and propose that cancer immunotherapies might be strongly dependent on in situ MHCII antigen presentation.

论文信息

作者
Kerdidani D、Aerakis E、Verrou KM、Angelidis I、Douka K、Maniou MA、Stamoulis P、Goudevenou K
单位
Institute of Bioinnovation, Biomedical Sciences Research Center "Alexander Fleming," Vari, Greece.Greece
文献类型
非美国政府资助研究
期刊
The Journal of experimental medicine2022 Feb 7
原文标识
PubMed 35029648 · DOI 10.1084/jem.20210815